SOPHiA GENETICS (NASDAQ:SOPH) Hits New 12-Month High – Time to Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH) shares hit a new 52-week high on Tuesday . The stock traded as high as $6.65 and last traded at $6.37, with a volume of 1935 shares trading hands. The stock had previously closed at $6.33.

Analyst Ratings Changes

SOPH has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday. HC Wainwright assumed coverage on SOPHiA GENETICS in a research report on Monday. They issued a “buy” rating and a $12.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

SOPHiA GENETICS Stock Performance

The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company has a market cap of $549.48 million, a PE ratio of -12.54 and a beta of 0.96. The firm’s 50-day simple moving average is $5.26 and its two-hundred day simple moving average is $5.03.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Insider Transactions at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. This trade represents a 1.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.17, for a total value of $38,221.81. Following the sale, the insider directly owned 614,887 shares of the company’s stock, valued at approximately $3,178,965.79. This represents a 1.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 176,711 shares of company stock worth $959,913 over the last 90 days. Insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS in the 2nd quarter worth approximately $567,000. Royal Bank of Canada lifted its stake in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares during the period. Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at $1,772,000. Principal Financial Group Inc. increased its stake in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the period. Finally, Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth $2,157,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.